Skip to main content
. Author manuscript; available in PMC: 2021 Jan 1.
Published in final edited form as: Am J Transplant. 2019 Sep 26;20(1):250–261. doi: 10.1111/ajt.15581

Figure 3: Association Between GCSF use and CLAD Development Among Propensity-Matched Cohort of Neutropenic Patients.

Figure 3:

Neutropenia groups represent severity of first episode of neutropenia. Time to CLAD is shown for patients with A) mild, b) moderate and c) severe neutropenia. For patients with mild neutropenia, GCSF administration was associated with a near significant increased risk for CLAD development (aHR 3.49, 95% CI 0.93–13.04, p=0.063). There were no significant differences in CLAD development for patients with moderate neutropenia, but patients with severe neutropenia who received GCSF had a near significant decreased risk for CLAD development according to whether or not they received GCSF (aHR 0.25, 95% CI 0.06–1.02, p=0.053).